Treatment Efficacy for Drug Abuse and AIDS Prevention - 2

This study has been completed.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) Mclean Hospital
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000211

Purpose

The purpose of this study is to assess the safety and effectiveness of buprenorphine for treatment of concurrent intravenous heroin and cocaine dependence.

Condition	Intervention	Phase
Cocaine-Related Disorders Heroin Dependence	Drug: Buprenorphine	Phase II

MedlinePlus related topics: Heroin

Drug Information available for: Buprenorphine Buprenorphine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Treatment Efficacy for Drug Abuse and AIDS Prevention

Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment:

Eligibility

Ages Eligible for Study:	26 Years to 41 Years
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000211

Locations

United States, Massachusetts
McLean Hospital, Dept. of Psychiatry
Belmont, Massachusetts, United States, 2178

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Mclean Hospital

Investigators

Principal Investigator:

Jack Mendelson, M.D.

Mclean Hospital

More Information

Study ID Numbers:	NIDA-06116-2, R18-06116-2
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000211
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Cocaine-Related Disorders
Buprenorphine
Mental Disorders
Heroin Dependence

Substance-Related Disorders
Disorders of Environmental Origin
Opioid-Related Disorders

Additional relevant MeSH terms:

Sensory System Agents
Therapeutic Uses
Narcotic Antagonists
Physiological Effects of Drugs
Central Nervous System Depressants
Narcotics

Peripheral Nervous System Agents
Analgesics
Central Nervous System Agents
Pharmacologic Actions
Analgesics, Opioid

ClinicalTrials.gov processed this record on January 15, 2009